Key result
Glycoprotein IIIa monoclonal antibody eluting stents reduced the ratio of stenosis compared to bare stents at 3 months.
Why the study?
Does a glycoprotein IIIa monoclonal antibody eluting stent reduce in-stent restenosis and improve endothelialization compared to a bare stent in rabbit iliac arteries?
Does a glycoprotein IIIa monoclonal antibody eluting stent reduce in-stent restenosis and improve endothelialization compared to a bare stent in rabbit iliac arteries?
A glycoprotein IIIa monoclonal antibody eluting stent accelerates endothelialization and reduces neointima proliferation and stenosis compared to bare stents in a rabbit model.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in rabbits; leaves open translation to human coronary restenosis prevention.
Since the percutaneous transtuminal coronary angioplasty was introduced into China in 1984, this procedure has become widely accepted as an important step in coronary revascularization. This study shows the effect of the monoclonal antibody (mAb) on the platelet glycoprotein IIIa receptor during endothelialization and in-stent restenosis by implanting the mAb-eluting stents into iliac arteries of rabbits. The hard tissue cross sections of the stent-implanted arterial segments were made by polymethylmethacrylate embedding. Arterial intima proliferation was observed and analyzed. The endothelialization of the stent surface was observed using scanning electron microscope, whereas the ultrastructure of the neointima was observed using transmission electron microscope. After one month of stent implantation, the surfaces of both groups were covered by intact endothelial layers, but the neointimal areas and the ratio of stenosis were significantly lesser in the mAb-eluting stent group (p < 0.01). After 3 months, the ratio of stenosis in the mAb-eluting stent group was 14.67 ± 0.79, whereas that of the bare stent group was 21.58 ± 1.76 (p < 0.01). Therefore, the mAb eluting from the stent surface has the potential to accelerate endothelialization, prevent thrombosis formation due to the interaction of stent with blood, and decrease the stenosis ratio by inhibiting neointima proliferation.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2012) studied in-stent restenosis. Glycoprotein IIIa monoclonal antibody eluting stent vs. bare stent was evaluated on ratio of stenosis at 3 months (p=<0.01). Glycoprotein IIIa monoclonal antibody eluting stents reduced the ratio of stenosis compared to bare stents at 3 months.
Synapse has enriched 10 related papers. Consider them for comparative context: